Janssen Pharms., Inc. et al. v. Teva Pharm. USA, Inc. et al., Appeal Nos. 2022-1258, -1307 (Fed. Cir. April 1, 2024)
In this week’s Case of the Week, the Federal Circuit vacated-in-part a district court’s bench trial...more
4/9/2024
/ Abstract Ideas ,
Appeals ,
Claim Construction ,
Janssen Pharmaceuticals ,
Obviousness ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
Prior Art ,
Remand ,
Teva Pharmaceuticals
Pfizer Inc. v. Sanofi Pasteur Inc., Appeal Nos. 2019-1871, -1873, -1875, -1876, -2224 (Fed. Cir. Mar. 5, 2024)
This week’s Case of the Week mostly resolves an appeal filed five years ago, following decisions from the...more
3/12/2024
/ Alice/Mayo ,
Appeals ,
Claim Construction ,
Inter Partes Review (IPR) Proceeding ,
Obviousness ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Remand ,
Reversal
In re: John L. Couvaras, Appeal No. 2022-1489 (Fed. Cir. June 14, 2023)
In our Case of the Week, the Court of Appeals for the Federal Circuit affirmed a Patent Trial and Appeals Board decision that a patent application’s...more
6/21/2023
/ Administrative Procedure Act ,
Appeals ,
Intellectual Property Protection ,
Nonobvious ,
Patent Act ,
Patent Invalidity ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Prior Art
Sequoia Technology, LLC v. Dell, Inc., Appeal Nos. 2021-2263, -2264, -2265, -2266 (Fed. Cir. April 12, 2023)
In an appeal from a stipulated judgment of noninfringement and invalidity following an adverse claim construction...more
4/18/2023
/ Anticipation ,
Appeals ,
Attorney's Fees ,
Claim Construction ,
Dismissal With Prejudice ,
Inter Partes Review (IPR) Proceeding ,
Noninfringement ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patent-in-Suit ,
Patents ,
Prior Art ,
Remand ,
Reversal ,
Section 101
Apple Inc. v. Vidal, Appeal No. 2022-1249 (Fed. Cir. Mar. 13, 2023)
In our Case of the Week, the Federal Circuit allowed Apple’s challenge to the Patent Trial and Appeal Board’s (“PTAB”) Fintiv rules to proceed, at least...more
3/21/2023
/ Administrative Procedure Act ,
Appeals ,
Claim Construction ,
Inter Partes Review (IPR) Proceeding ,
Noninfringement ,
Notice and Comment ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Prior Art ,
Remand ,
Rulemaking Process ,
USPTO
International Business Machines Corp. v. Zillow Group, Inc. et al., Appeal No. 2021-2350 (Fed. Cir. 2022) -
In this week’s Case of the Week, the Federal Circuit affirmed a Rule 12(c) judgment on the pleadings that IBM’s...more
In re: Volkswagen Group of America, Inc. and In re: Hyundai Motor America, Appeal Nos. 2022-108, -109 (Fed. Cir. Mar. 9, 2022) -
In the most recent of multiple mandamus rulings issued by the Federal Circuit in relation to...more
3/15/2022
/ Appeals ,
Claim Construction ,
Dismissals ,
Improper Venue ,
Inter Partes Review (IPR) Proceeding ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Vacated ,
Venue ,
Writ of Mandamus ,
Written Descriptions
Adapt Pharma Operations Limited v. Teva Pharmaceuticals USA, Inc., Appeal No. 2020-2106 (Fed. Cir. Feb. 10, 2022) -
In our Case of the Week, the Court of Appeals for the Federal Circuit, in both the majority opinion and...more
2/15/2022
/ Appeals ,
En Banc Review ,
Inter Partes Review (IPR) Proceeding ,
IP License ,
Motion To Seal ,
Obviousness ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
Preliminary Injunctions ,
Prior Art ,
Remand ,
Third-Party ,
Vacated